SoftBank wants to push Neumann out of the CEO role ahead of the IPO.Technologyread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
Microsoft is looking for a new way to grab business from retailers as they fend off Amazon.Technologyread more
The UK's Civil Aviation Authority said Thomas Cook had now ceased trading and the regulator would work with the government to bring the more than 150,000 British customers...Europe Marketsread more
The holidays are a critical time for many brands, as sales during this time of year can make up 30% of a retailers annual sales. Heading into the gift-giving season, shoppers...Retailread more
An annual survey by Piper Jaffray found iPhone users willing to upgrade to newly released models declined compared to last year.Technologyread more
Banks have historically used armies of mortgage brokers to gather income and asset documents from prospective borrowers.Financeread more
Guggenheim reiterates its buy rating on Boston Beer's stock and raises its price target to $462 from $449 per share.Investingread more
On-demand delivery company Postmates is partnering with Phantom Auto, an autonomous vehicle teleoperator, to coordinate driverless deliveries.Autosread more
Oprah Winfrey is bringing her famed book club to Apple's new streaming subscription service.Technologyread more
Bruce Broussard, CEO of health insurance company Humana, sits down with CNBC's Bertha Coombs to discuss the state of the industry, integrating digital health technology,...Squawk Boxread more
Billionaire hedge fund boss Bill Ackman told CNBC on Friday the past 12 months were the "worst period of performance" of his investment career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
"It's almost entirely been driven by Valeant. I've never owned a stock down 90 percent," the Pershing Square Capital Management chief told "Squawk Box," referring to Valeant's plunge from a 52-week high of $245 per share to around $18 per share in late June.
Since then Valeant has recovered to around $31 per share, as the embattled drugmaker works to regain investor confidence after questions about its pricing strategy and ties to a specialty pharmacy led to wider political and regulatory scrutiny, and hammered the stock.
Ackman, who joined the Valeant board in mid-March, said the company is making progress. In addition to revamping its board, Valeant earlier this year hired Joseph Papa, chief executive of over-the-counter drug company Perrigo, as its new CEO to succeed longtime chief Michael Pearson. Valeant in August named Paul Herendeen, an executive at animal drugmaker Zoetis, as its chief financial officer.
"[Valeant] is now a more traditional Pershing Square investment" now that it's been pummeled, he said. "We normally invest when shareholders have lost confidence in management. And that's what happened here. It was not just management, shareholders lost confidence in the numbers. The financial statements were delayed. There was a potential default."
Ackman said he broke all his investment rules with Valeant, initially striking up a partnership with the Canadian drugmaker in 2014 to try to buy Botox-maker Allergan. The unique arrangement raised questions at the time about a conflict of interest, an assertion Ackman had dismissed.
"We went off the reservation," he told CNBC on Friday, looking back at those early days. "We made one very big mistake taking a passive position in Valeant."
"We never normally get to meet the management of a company before making an investment. [And] we never invest in really complicated companies you can't figure out from just reading the 10K [filing]," he said.
Actavis ultimately thwarted Valeant, and purchased Allergan last year in a deal valued at $66 billion.
Once the Allergan deal was lost, Ackman stuck with Valeant in hopes to strike other deals. "We thought we could help, as we attempted to do in the Allergan transaction, by creating other potential merger opportunities. That was a big mistake."
Ackman's Valeant comments Friday on "Squawk Box" were part of a wide-ranging interview that also dealt with the billionaire's Herbalife short. The Pershing Square founder said he was approached to purchase Carl Icahn's stake in the nutritional supplement firm.